Upstream Manufacturing Solutions

  1. Exceptional Precision, Scalability, And Control For Your Bioprocessing 12/5/2025

    Bioprocessing professionals face growing demands for faster development. Transition smoothly from early-stage research to commercial-scale production with the latest innovations for bioreactors.

  2. Immunoassays For Cytokine And Chemokine Quantitation 12/5/2025

    Achieve precise cytokine and chemokine quantitation with flexible immunoassay solutions, including multiplexed bead-based assays, ELISA kits, and ELISPOT reagents, for human, rat, and mouse studies.

  3. Minimize Spillover Spread And Improve Panel Resolution 12/5/2025

    Unlock cleaner flow cytometry data with engineered fluorochromes that reduce spillover and boost resolution. Design complex panels easily across conventional and spectral systems.

  4. Expand Your T-Cell Research With Confidence 12/5/2025

    Achieve deeper T-cell characterization with a panel designed for flexibility. Streamline multicolor panel design, see higher resolution markers, and enable intracellular cytokine detection together.

  5. Phosphitylating And Phosphorylating Agents 11/25/2025

    Explore essential phosphitylating and phosphorylating agents used in API synthesis and oligonucleotide preparation for cell and gene therapy applications.

  6. Oligonucleotide Manufacturing: End-To-End Solutions To Enable Large-Scale Processing 11/24/2025

    Discover end-to-end solutions for challenging large-scale oligonucleotide manufacturing. Optimize processes across the entire value chain to enable ultra-high purity and cost-effective commercialization.

  7. CHO Edge System 11/24/2025

    Achieve high monoclonal antibody and complex bispecific titers routinely with an IND-approved cell line development platform that integrates genetic tools and data-driven models.

  8. LV Edge System 11/24/2025

    By transitioning from a 4-plasmid transient system to 1- or 0-plasmid configurations, the LV Edge systems reduce or eliminate the need for GMP plasmids, lowering costs and supply chain risks.

  9. AAV Edge System 11/24/2025

    Learn about a modular tool suite capable of achieving titers up to 6E15 vg/L. Move from transfection to stable cell lines in just 20 weeks using AI-driven optimization and robust host platforms.

  10. Powering Production Of Viral Vector-Based Therapies 11/14/2025

    Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.